Track topics on Twitter Track topics that are important to you
Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation articles that have been published worldwide.
We have published hundreds of Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation news stories on BioPortfolio along with dozens of Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation Clinical Trials and PubMed Articles about Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation Companies in our database. You can also find out about relevant Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation Drugs and Medications on this site too.
Successful eradication of recurrent hepatitis C virus (HCV) infection following liver transplantation (HCV) improves graft survival. The current study aimed at evaluation of hepatic fibrosis changes among long term responders to DAAs therapy for recurrent HCV after liver transplantation using noninvasive methods. Patients with significant hepatic fibrosis (≥F2) who achieved SVR12 after treatment with DAAs for recurrent HCV were included (n=52). Hepatic fibrosis status was assessed, non-invasively, by calc...
Liver transplantation is viewed as a panacea for morbidity and mortality related to end stage liver disease although post-transplant survival still remains around 90% and 70% at 1 and 5 years, respectively. Judicious assessment of patients before transplantation is imperative to enhance optimal candidate selection and post-operative outcomes (1). One of the important consequences of malnutrition, sarcopenia and deconditioning is frailty, which is increasingly being recognized as a contributor to morbidity a...
Liver transplantation is considered the best therapy option for end-stage liver disease. Different factors including recipient comorbidity at time of transplantation are supposed to have substantial impact on outcomes. Although several studies have focused on comorbidity assessment indices for liver transplant recipients, there is no systematic review available on the methodological details and prognostic accuracy of these instruments. The aim of this study is to systematically review recipient comorbidity ...
Hyperammonemia is a rare and important complication post-liver transplantation. We review a case of a 5-month-old boy with biliary atresia who received a split liver transplant following a variceal bleed. The transplant was complicated by recurrent portal vein thrombosis. Colonized with Serratia marcescens pretransplant, he developed disseminated infection associated with very high levels of ammonia that led to his death. It is important to be aware of serum ammonia levels in patients with portal vein throm...
Cardiovascular disease (CVD) is a leading cause of post-liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across U.S. hospitals.
Hepatic encephalopathy (HE) is a major cause of morbidity in cirrhosis. However its severity assessment is often subjective, which needs to be studied systematically.
Coronary artery disease (CAD) assessment is vital part of liver transplantation (LT) evaluation as it allows for identification and medical optimization prior to transplantation. Although aspirin and statins are standard of care for CAD, they are not universally used in cirrhosis due to concerns of adverse events.
Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the post-transplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pre-transplant patients with advanced liv...
The liver exhibits intrinsic immune tolerogenic properties that contribute to a unique propensity toward spontaneous acceptance when transplanted, both in animal models and in humans. Thus, in contrast to what happens after transplantation of other solid organs, several years following liver transplantation a significant subset of patients are capable of maintaining normal allograft function with histological integrity in the absence of immunosuppressive drug treatment. Significant efforts have been put int...
Mixed hepatocellular-cholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular and biliary differentiation. While liver transplantation (LT) is the gold standard treatment for patients with unresectable hepatocellular carcinoma (HCC), it is contraindicated in known HCC-CCA due to concerns of poor prognosis. We sought to compare post-transplant oncologic outcomes for HCC-CCA and a matched cohort of HCC LT recipients.
Live attenuated vaccines are currently contraindicated in solid-organ transplant recipients. However, the risk of vaccine-preventable infections is lifelong, and can be particularly severe after transplantation. In this prospective interventional national cohort study, 44 pediatric liver transplant recipients with measles IgG antibodies
Risk analysis of cold ischemia time (CIT) in liver transplantation has largely focused on patient and graft survival. Post-transplant length of stay is a sensitive marker of morbidity and cost. We hypothesize that CIT is a risk factor for post-transplant prolonged length of stay (PLOS) and aim to conduct an hour-by-hour analysis of CIT and PLOS.
Liver transplant (LT) improves daily function and ameliorates gut microbial composition. However, the effect of LT on microbial functionality, which can be related to overall patient benefit, is unclear and could affect the post-LT course.
Since the implementation of the MELD score-based allocation system, the number of transplant candidates with impaired renal function has increased. The aims of this review are to present new insights in the definitions and predisposing factors that result in acute kidney injury (AKI), and to propose guidelines for the prevention and treatment of post liver transplantation (LT) AKI. This review is based on both systematic review of relevant literature and expert opinion. Pretransplant AKI is associated with ...
We report a case of post-transplant liver graft infection with Schistosoma spp in a migrant from Sub-Saharan Africa transplanted for HBV-related cirrhosis and with undiagnosed schistosomiasis pre-transplantation. The occurrence of tropical diseases in non-endemic areas warrants screening protocols for organ donors and recipients with a history of exposure in endemic areas. This article is protected by copyright. All rights reserved.
Liver transplantation (LT) is a complex yet curative treatment for a subset of patients with hepatocellular carcinoma (HCC). Due to donor organ shortage, patients with HCC need to be carefully selected for LT. In European countries, selection of patients is based on the Milan criteria, and donor organs are allocated by Eurotransplant. In order to optimize the utilization of available liver grafts, the outcome of HCC patients after LT needs to be closely monitored and evaluated.
Non-alcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the next decade in the United States. Strategies to treat the underlying etiology of NASH, which is almost always obesity, are being pursued. One such strategy is the utilization of bariatric surgery in the peri-transplant period. The use of bariatric surgery prior to LT could prevent the progression of NASH, and abrogate the need for LT. Bariatric surgery at the time of LT or post-operativel...